Target Name: ZNF232
NCBI ID: G7775
Review Report on ZNF232 Target / Biomarker Content of Review Report on ZNF232 Target / Biomarker
ZNF232
Other Name(s): ZSCAN11 | zinc finger and SCAN domain-containing protein 11 | Zinc finger protein 232 (isoform a) | ZN232_HUMAN | Zinc finger and SCAN domain-containing protein 11 | Zinc finger protein 232 | ZNF232 variant 1 | zinc finger protein 232 | Zinc finger protein 232, transcript variant 1

ZNF232: A Potential Drug Target for Cancer and Neurodegenerative Diseases

ZNF232 (ZSCAN11) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the ZNF2 gene family, which is known for its role in regulating gene expression and cell signaling. ZNF232 has been identified as a potential drug target (or biomarker) due to its involvement in several disease processes, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ZNF2 gene family is composed of four genes: ZNF2, ZNF3, ZNF4, and ZNF5. All of these genes encode for proteins that share a similar structure and function. ZNF232 is a member of the ZNF2 gene family and is responsible for the production of a protein that is similar to ZNF212. ZNF212 is a key regulator of stem cell proliferation and has been implicated in several diseases, including cancer.

ZNF232 is involved in several signaling pathways that are important for cell growth, differentiation, and survival. One of the well-established functions of ZNF232 is its role in the TGF-β pathway, which is a critical pathway for cell signaling and growth. TGF-β signaling is involved in the regulation of cell proliferation, differentiation, and survival, and is a target of many drugs that are used to treat cancer and other diseases.

ZNF232 is also involved in the Wnt signaling pathway, which is involved in the regulation of cell growth and differentiation. Wnt signaling is a critical pathway for the development and maintenance of tissues, including the nervous system and the placenta. Alterations in the Wnt signaling pathway have been implicated in several diseases, including neurodegenerative diseases.

In addition to its involvement in the TGF-β and Wnt signaling pathways, ZNF232 is also involved in theNotch signaling pathway. Notch signaling is involved in the regulation of cell survival and proliferation, and is a target of several drugs that are used to treat cancer and other diseases.

The potential drug targets for ZNF232 are numerous. Its involvement in the TGF-β pathway makes it a potential target for drugs that are used to treat cancer, including breast and ovarian cancers. ZNF232 is also a target for drugs that are used to treat neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. In addition, ZNF232 is involved in the regulation of stem cell proliferation, which makes it a potential target for drugs that are used to treat acute myeloid leukemia and other blood cancers.

ZNF232 is also a potential biomarker for several diseases, including cancer. Its expression has been detected in a variety of cancer tissues, including breast, ovarian, and colorectal cancers. By using ZNF232 as a biomarker, researchers can monitor the effectiveness of cancer treatments and track disease progression.

In conclusion, ZNF232 is a protein that is involved in several signaling pathways that are important for cell growth, differentiation, and survival. Its involvement in these pathways makes it a potential drug target (or biomarker) for a variety of diseases, including cancer. Further research is needed to fully understand the role of ZNF232 in disease and to develop effective treatments.

Protein Name: Zinc Finger Protein 232

Functions: May be involved in transcriptional regulation

The "ZNF232 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF232 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A